Enterprise AI governance is becoming table stakes. But the enterprise isn't monolithic. A pharma company, a biotech firm, and a financial services company face fundamentally different regulatory demands when deploying AI — yet most enterprises buy the same horizontal platform and expect it to work for all three.
It doesn't.
Over the past eighteen months, I've watched dozens of regulated enterprises discover this the hard way. They choose a horizontal AI governance platform — the kind designed to work across finance, retail, manufacturing, healthcare, and insurance. Six months in, they're hiring consultants to bolt on FDA controls, building custom workflows for GxP change management, and running manual evidence collection cycles before every audit. A year later, they realize they bought the wrong tool.
Life sciences is vertical. It has its own regulatory grammar. And horizontal platforms weren't built to speak it.
The Appeal of Horizontal AI Governance Platforms
The sales pitch is compelling. A single platform handles AI governance across your entire enterprise. Finance gets model risk controls. Manufacturing gets safety guardrails. Life sciences gets... the same controls, configured differently.
The promise is efficiency: deploy once, configure for each business unit, scale globally. The price tag is lower than building custom solutions. The feature set is broader. And the vendor has the resources of a large enterprise security company behind it.
It's easy to see why CTOs and procurement teams choose horizontal. When you're evaluating platforms, lower cost and broader capabilities feel like a win.
But life sciences doesn't work that way.
Why Enterprises Initially Choose Horizontal
The decision logic is sound in the abstract. A horizontal platform means:
These are real advantages. They're just not enough to overcome what comes next.
The Regulatory Gap: Life Sciences Has Different Rules
Pharma, biotech, and medical devices operate under a regulatory regime that's fundamentally different from other industries. These aren't niche requirements. They're foundational.
FDA 21 CFR Part 11 Is Pharma-Specific
21 CFR Part 11 is the FDA's rule for electronic records and signatures. It was written in 1997, before modern AI, but its principles are non-negotiable for any regulated pharmaceutical manufacturer. Part 11 requires:
A horizontal platform logs activity. Life sciences needs FDA-compliant evidence records. These aren't the same thing. Audit trails in generic platforms don't meet Part 11's specificity requirements for pharmaceutical data.
EU AI Act High-Risk Categories Apply to Life Sciences
The EU AI Act designates medical devices, drug discovery, and clinical decision support as "high-risk" AI systems. High-risk systems require:
A horizontal platform treats "high-risk" as a configuration flag. Life sciences needs high-risk as a design principle that shapes every workflow, every audit trail, every escalation path.
GxP Requirements Are Life Sciences-Specific
Good Manufacturing Practice (GxP) is the umbrella covering GMP (manufacturing), GLP (lab studies), GCP (clinical trials), and GDP (distribution). GxP isn't a checklist — it's a governance philosophy that requires documented evidence for every material decision.
GxP change control, for example, isn't just version tracking. It's:
A horizontal platform has "change management workflows." Life sciences needs GxP-aligned change control with quality gates, risk assessments, and compliance evidence baked in.
HIPAA Is Stricter Than Generic Privacy
Healthcare data under HIPAA has stricter access controls, audit requirements, and breach notification timelines than generic privacy frameworks. HIPAA's Security Rule requires:
A horizontal platform handles GDPR and CCPA compliance. HIPAA compliance requires healthcare-specific controls that generic privacy frameworks don't provide.
The Result: Control Gaps Across the Board
When these regulatory frameworks stack on top of each other — and in life sciences, they do — horizontal platforms have gaps. The gaps aren't small. They're foundational.
80% of enterprises using horizontal platforms for life sciences require custom development to achieve compliance. That's not a configuration challenge. That's an architecture problem.
The Operational Gap: GxP-Aligned Workflows
Regulatory compliance is one thing. Operational alignment is another.
A horizontal platform has generic "approval workflows." A process owner defines a workflow: "Submit approval request → Manager reviews → Manager approves." The system routes the request, tracks approval, and logs the decision.
Life sciences needs GxP workflows. Here's what that looks like in practice:
A pharma company deploys Claude Managed Agents to help pharmacists screen potential drug candidates. The agent runs a research protocol, evaluates compounds, and recommends six candidates for further testing. The agent doesn't just output a list — it documents its reasoning, flags assumptions, and notes edge cases.
For the recommendation to enter the regulated process, it requires:
A horizontal platform routes this to "Manager" with a generic approval checkbox. A GxP-aligned platform understands that "Quality Lead" is a role with specific authority, that "risk assessment" is a distinct step in the workflow, and that "training evidence" is a compliance obligation tied to the approval.
The difference isn't in the number of steps. It's in the grammar. Horizontal platforms use generic governance language. Life sciences needs GxP dialect built into the workflow engine itself.
The Evidence Gap: Audit-Ready Documentation
Here's where the real cost emerges.
A horizontal platform logs activity. User X submitted model Y at timestamp Z. User A approved at timestamp W. That's an event log. It's accurate. It's useful for operational debugging.
Life sciences audits don't ask "What happened?" They ask "Prove that what you did was right."
FDA audits demand evidence. Specifically:
With a horizontal platform, your audit trail shows the approval happened. Your audit readiness requires you to manually compile the justification, validation, and supporting evidence into a binder for the FDA investigator to review.
The cost is brutal. A typical pharmaceutical company runs a 21 CFR Part 11 audit every 18–24 months. With a horizontal platform, the evidence collection and documentation process takes 40–60 hours per audit cycle. Your compliance team gathers supporting docs, maps them to audit scope, builds an evidence book, and preps for investigator questions.
With a purpose-built platform, your evidence collection takes 10–15 hours because the platform captures evidence as part of the compliance workflow. The evidence book is generated automatically. The audit trail already contains the contextual metadata the FDA requires.
That's not a nice-to-have. Over a three-year period, that's 75–150 hours of annual compliance labor — the difference between a compliance manager doing her core job and a compliance manager spending half her year auditing herself.
The Agentic AI Gap: Where Horizontal Platforms Truly Fall Short
Most AI governance discussions happen in the past tense. We governed models. We tracked deployments. We logged inferences. This framework assumes humans author the AI system, humans deploy it, and AI executes within defined boundaries.
Agentic AI changes the equation.
An agentic AI system makes decisions, takes actions, and evaluates outcomes autonomously. A life sciences application might be: an agent that monitors clinical trial data in real time, flags safety signals, escalates to the clinical operations team, and proposes protocol adjustments. The agent doesn't just analyze — it acts. It operates within guard rails, but it operates.
Horizontal platforms treat AI governance as model governance. They track model versions, log predictions, and monitor drift. These are important. But they don't address agentic governance:
A purpose-built platform for life sciences builds agentic governance into the architecture. It captures agent decisions, documents the reasoning context, enforces human escalation rules that align with GxP authority structures, and produces audit-ready evidence that the agent was properly governed.
Horizontal platforms have no answer for this. They're still building it. Life sciences can't wait.
Case Study: Migration from Horizontal to Vertical
I'll describe a composite scenario because the details vary, but the pattern is consistent across firms we work with.
A pharmaceutical manufacturer spent $400K on a horizontal AI governance platform. The vendor promised to work with regulated industries. The platform had strong data governance, model tracking, and deployment controls.
Six months in, the pharma company was in trouble.
They needed to govern Claude Managed Agents running drug target discovery. The agents analyzed biomarker data, cross-referenced efficacy signals, and recommended new therapeutic targets for validation studies. The agents operated within guardrails, but they made material recommendations.
The horizontal platform could track agent deployments and log agent outputs. It couldn't capture the evidence that regulators require:
The pharma company spent the next six months configuring custom workflows, building approval matrices, and manually documenting evidence. They hired a consulting firm to help design GxP-aligned escalation rules. By month twelve, they'd spent an additional $500K+ and were still six months behind their deployment schedule.
The audit window was opening. Their compliance team was nervous. The platform vendor couldn't help — these requirements were outside their design scope.
They made the decision to migrate to BioCompute. Baseline configuration — FDA 21 CFR Part 11, EU AI Act, GxP change control, HIPAA audit trails, agentic governance — took six to eight weeks. By week ten, they had fully compliant evidence collection running. The agents were properly governed. Audit preparation took 12 hours instead of 60.
Migration cost: $150K. Timeline: 10 weeks. Result: fully auditable, fully compliant, fully operational AI agents.
The company did the math. Horizontal platform plus consulting plus custom development plus delay: $900K+ and a year of schedule slip. Purpose-built platform: $150K and two months of onboarding.
The horizontal platform wasn't a bad product. It was the wrong product for the job.
The Cost of Choosing Wrong
This is the decision that matters.
When you choose a horizontal platform for life sciences, you're not just buying software. You're committing to a support and consulting budget that will exceed the platform cost itself. You're accepting schedule risk that translates to delayed deployments and missed market windows. You're creating compliance risk because your audit trails don't match regulatory requirements.
Total cost of ownership breaks down like this:
- Horizontal Platform + Custom Development:
- Platform licensing: $400K–$800K over three years
- Implementation and configuration: $300K–$500K
- Ongoing consulting for GxP workflows: $150K–$300K annually
- Compliance labor (manual evidence collection): $100K–$200K annually
- Risk cost (audit failures, remediation): unquantified, but material
Total over three years: $1.2M–$2.3M
- Purpose-Built Vertical Platform:
- Platform licensing: $300K–$500K over three years
- Implementation and baseline: $100K–$150K (one-time)
- Ongoing compliance support: $0–$50K annually (built-in)
- Compliance labor (automated evidence collection): $25K–$50K annually
Total over three years: $450K–$800K
The vertical approach costs 40–50% less over three years. But more important: it eliminates the schedule risk, the audit risk, and the expertise gap that comes with horizontal.
Vertical Approaches: The Difference
A purpose-built life sciences AI governance platform is built from the ground up for regulated environments. It understands the regulatory grammar because it was designed by people who speak it.
BioCompute is purpose-built for regulated AI in life sciences. It includes:
Implementation takes six to eight weeks because the platform speaks your regulatory language natively. Configuration isn't guesswork — it's alignment with frameworks designed by the people who regulate your industry.
The baseline is already compliant. Your team configures for your specific validated systems and processes. The evidence collection happens automatically. Your audit preparation is a review, not a reconstruction.
This isn't about features. Horizontal platforms have features too. It's about grammar. It's about whether your governance platform understands the regulatory, operational, and compliance context of life sciences.
The Path Forward
If you're currently using a horizontal platform for life sciences AI governance, the conversation isn't whether you should switch. The conversation is when, and what the transition looks like.
If you're evaluating now, the path is clearer. Choose a platform built for your industry. The cost of choosing wrong compounds over time — in compliance labor, in audit risk, in deployment delays.
Life sciences doesn't fit a horizontal mold. Your AI governance platform shouldn't try to.